drugset / Trial / NCT01849042

Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease

NCT01849042

Phase 4 Unknown 188 enrolled Konkuk University Medical Center
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the pharmacological efficacy on language capability and compliance with combination of new Ebixa oral pump and donepezil compared to donepezil only in patients with probable Alzheimer's disease. Primary objective is to evaluate the efficacy of memantine on language capability in moderate to severe Alzheimer's disease patients who are taking stable donepezil treatment.Secondary objectives are to evaluate the efficacy of maintain on cognitive function and disease progression with K-MMSE, NPI, ROSA, and SIB-short form in probable AD.

Timeline

Start
2013-01
Primary completion
2014-08
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Memantine Unknown 20 mg Oral
Background Donepezil Small molecule 5 mg
Background Donepezil Small molecule 10 mg

Indications